Industry views - H. Lundbeck A/S

Lundbeck_600

Does good work equal good health in working patients with MDD

Pratap Chokka


What do clinical goals mean to patients with schizophrenia?

Sofia Brissos


Are relapse prevention and functioning sufficiently prioritized in the treatment of schizophrenia?

Article

 

Should we challenge the way we assess functioning?

Michael Taylor 


Can we be bothered about apathy? Approaching negative symptoms in schizophrenia

Article

 

Towards a focus on the science in treatment classifications

Article

 

Targeting what matters most for patients with depression: Strategies for promoting full functional recovery

Article

 

Getting the patients’ perspective on the impact of antipsychotic side effects – Part 1

Rajiv Tandon 


Getting the patients’ perspective on the impact of antipsychotic side effects – Part 2

Rajiv Tandon


Getting the patients’ perspective on the impact of antipsychotic side effects – Part 3

Rajiv Tandon


Early psychosis intervention works, but can we move to prevention?

Article

 

Treatment outcomes in schizophrenia – what matters to patients?

Article

 

Patient goals and measuring outcome crucial in MDD

Article

 

Emotional blunting: unresolved MDD symptom or effect of treatment?

Article

Emotional blunting

 

This webpage was developed in collaboration with H. Lundbeck A/S.